Jupiter Neurosciences
Business Services · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1001 N Us Hwy 1 Ste 504, Jupiter, Florid...Phone Number
(561) 406-6154Website
www.jupiterneurosciences.comRevenue
<$5 MillionStock Symbol
JUNSIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Jupiter Neurosciences
Jupiter Neurosciences is a clinical-stage drug platform company focused on treating neuroinflammation. Established in 2020, Jupiter Neurosciences is headquartered in Jupiter, Florida, United States.Explore more
Jupiter Neurosciences Org Chart
AR
Co-Founder, CAO
JP
Controller
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Jupiter Neurosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Jupiter Neurosciences has new funding data
Jupiter Neurosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Jupiter Neurosciences recently announced quarterly report
Product Launch: Get notified when Jupiter Neurosciences launches new products
Check if Jupiter Neurosciences has recently received funding, and reach out quickly before it becomes old news!
Check out if Jupiter Neurosciences is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Jupiter Neurosciences
Click to see if Jupiter Neurosciences had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Jupiter Neurosciences as Masked Content
Find 3 more new buyers
Compare Similar Companies to Jupiter Neurosciences
Compare insights from companies similar to Jupiter Neurosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Jupiter Neurosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Jupiter Neurosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Jupiter Neurosciences.
Jupiter Neurosciences Tech Stack
A closer look at the technologies used by Jupiter Neurosciences
See more technologies
Most Recent Scoops
Project
Product Development, Product Management, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Partnership
Partnership, Product Development, Research & Development, Product Management, Inventory Management, Medical Research, Clinical Operations, Contracts
Earnings
Earnings, Finance
Left Company
Executive Move
Dana Perez has stepped down from the role of Chief Financial Officer. Perez will remain with the company as a consultant.
New Hire
Executive Move
Jupiter Neurosciences News & Media
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity PositionJupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering.PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002 to Jupiter Neurosciences in a Transaction Valued at Over $100 Million USDJupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Jupiter Neurosciences
Sign Up For FreeTo access detailed company insights
Jupiter Neurosciences is a clinical-stage drug platform company focused on treating neuroinflammation. Established in 2020, Jupiter Neurosciences is headquartered in Jupiter, Florida, United States.... Read More
